for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Dyne Therapeutics Inc

DYN.N

Latest Trade

6.86USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

6.77

 - 

22.67

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
6.86
Open
--
Volume
--
3M AVG Volume
5.36
Today's High
--
Today's Low
--
52 Week High
22.67
52 Week Low
6.77
Shares Out (MIL)
51.53
Market Cap (MIL)
368.43
Forward P/E
-2.46
Dividend (Yield %)
--

Next Event

Q4 2021 Dyne Therapeutics Inc Earnings Release

Latest Developments

More

Deep Track Capital Lp Reports 5.47% Passive Stake In Dyne Therapeutics Inc As Of January 18, 2022 - SEC Filing

Dyne Therapeutics Announces FDA Clinical Hold On Ind Application For Dyne-251 In Duchenne Muscular Dystrophy

Dyne Therapeutics Announces Submission Of Ind Application To Initiate Clinical Trial Of Dyne-251 For Duchenne Muscular Dystrophy

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Dyne Therapeutics Inc

Dyne Therapeutics Inc. is building a muscle disease company. The Company is focused on advancing therapeutics for patients with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that it has designed to target the genetic basis of the disease. With its FORCE platform, it has the flexibility to deploy different types of oligonucleotide payloads with specific mechanisms of action that modify target functions. Using its FORCE platform, the Company is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker.

Industry

Biotechnology & Drugs

Contact Info

830 Winter Street

WALTHAM, MA

02451

United States

+1.781.7868230

https://www.dyne-tx.com/

Executive Leadership

Jason Rhodes

Chairman of the Board

Joshua T. Brumm

President, Chief Executive Officer, Director

Susanna Gatti High

Chief Operating Officer

Ashish Dugar

Senior Vice President - Global head of Medical Affairs

Oxana Beskrovnaya

Chief Scientific Officer

Key Stats

1.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2020

0.0K

2021(E)

0.0K
EPS (USD)

2020

-4.130

2021(E)

-2.908
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
0.89
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-30.76
Return on Equity (TTM)
-29.74

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up